Shire PLC’s (SHP) “Overweight” Rating Reiterated at JPMorgan Chase & Co.
Other equities research analysts have also recently issued research reports about the stock. Deutsche Bank AG reissued a buy rating and issued a GBX 5,600 ($73.10) target price on shares of Shire PLC in a research report on Monday, June 13th. Royal Bank Of Canada reissued an outperform rating on shares of Shire PLC in a research report on Friday, July 22nd. Jefferies Group boosted their target price on shares of Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the company a buy rating in a research report on Wednesday, August 3rd. Citigroup Inc. reissued a buy rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Finally, Credit Suisse Group AG boosted their target price on shares of Shire PLC from GBX 5,000 ($65.27) to GBX 5,200 ($67.88) and gave the company an outperform rating in a research report on Wednesday, August 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of Buy and an average price target of GBX 5,828 ($76.07).
Shire PLC (LON:SHP) opened at 5114.00 on Monday. Shire PLC has a 1-year low of GBX 2,707.19 and a 1-year high of GBX 5,377.00. The firm’s market capitalization is GBX 34.92 billion. The firm’s 50-day moving average is GBX 4,981.22 and its 200-day moving average is GBX 4,556.22.
The company also recently disclosed a dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 8th will be paid a GBX 3.51 ($0.05) dividend. This represents a dividend yield of 0.07%. The ex-dividend date is Thursday, September 8th.
In other news, insider Dominic Blakemore acquired 133 shares of the stock in a transaction dated Friday, September 30th. The stock was bought at an average price of GBX 5,010 ($65.40) per share, with a total value of £6,663.30 ($8,697.69).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.